文献速递腹部技术与安全CT

肝脏马赛克强化模式与克罗恩病炎症活动及不良治疗结局相关

Hepatic mosaic enhancement pattern correlates with increased inflammatory activity and adverse therapeutic outcomes in patients with Crohn's disease.
PubMed 文献 · Abdom Radiol (NY) · 2021-03-01

本研究纳入25例CT显示肝脏马赛克强化模式(HMEP)的克罗恩病患者与25例无HMEP匹配患者,比较临床、实验室及内镜指标。HMEP组CRP、ESR、血小板更高,抗炎治疗后缓解率显著低于非HMEP组(P=0.045)。结论提示HMEP与克罗恩病炎症活动增加及不良治疗结局相关。

要点

  • 克罗恩病患者CT检出肝脏马赛克强化模式时,提示炎症活动度可能更高。
  • HMEP组抗炎治疗后1年缓解率显著低于非HMEP组(P=0.045)。
  • HMEP组CRP(P=0.001)、ESR(P=0.013)、血小板(P=0.005)均高于非HMEP组。

关键影像表现/征象

  • HMEP组瘘管/脓肿发生率84%(21/25)高于非HMEP组48%(12/25),但差异无统计学意义(P=0.056)。

诊断标准与关键数值

  • 治疗结局中活动性炎症定义为:有内镜数据时CDEIS > 3.5,无内镜数据时C反应蛋白水平 > 5 mg/L;否则为缓解。
  • HMEP组抗炎治疗后缓解率显著低于非HMEP组(P=0.045)。
  • HMEP组C反应蛋白水平高于非HMEP组(P=0.001)。
  • HMEP组红细胞沉降率高于非HMEP组(P=0.013)。
  • HMEP组血小板计数高于非HMEP组(P=0.005)。

临床应用与阅片要点

  • 在克罗恩病患者的腹部CT阅片时,可关注是否存在肝脏马赛克强化模式,该征象可能提示炎症活动度更高。
  • HMEP患者随访中可能更需关注抗炎治疗后的缓解情况,原文显示该组缓解率较低。
  • 两组治疗策略无显著差异(P=0.509),HMEP组的较差结局并非由治疗策略差异解释。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: This study aimed to evaluate the role of hepatic mosaic enhancement pattern (HMEP) on computed tomography images in the disease activity and therapeutic outcome of Crohn's Disease (CD).

METHODS: Twenty-five CD patients with HMEP comprised the HMEP group, and 25 CD patients without HMEP, who had a similar onset age, sex, and disease course with those in the HMEP group, comprised the non-HMEP group. No underlying liver/biliary disease was observed in any of the patients. Clinical characteristics, laboratory test results, Lémann index, and CD endoscopic index of severity (CDEIS) were compared between the groups using the Student t-, Mann-Whitney U, Chi square, or Fisher's exact tests. Patients received top-down, step-up, or traditional treatment during the follow-up period. After the 1-year follow-up, therapeutic outcomes (active inflammation [CDEIS > 3.5 if the endoscopic data were available, or C-reactive protein level > 5 mg/L if the endoscopic data were unavailable] or remission) were evaluated.

RESULTS: The occurrence rate of fistulas/abscesses was higher in the HMEP group (84%, 21/25) than in the non-HMEP group (48%, 12/25) with no statistical significance (P = 0.056). The HMEP group showed a higher C-reactive protein level (P = 0.001), erythrocyte sedimentation rate (P = 0.013), and blood platelet count (P = 0.005). There was no significant difference in therapeutic strategies between the groups (P = 0.509). The HMEP group showed a significantly lower remission ratio after anti-inflammatory treatment than the non-HMEP group (P = 0.045).

CONCLUSIONS: HMEP was correlated with increased inflammatory activity and adverse therapeutic outcomes in CD. This finding provided insights regarding novel markers of CD diagnosis and treatment.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Shi L, Lu BL, Qiu Y, et al. Hepatic mosaic enhancement pattern correlates with increased inflammatory activity and adverse therapeutic outcomes in patients with Crohn's disease. Abdom Radiol (NY). 2021. PMID: 33646351. doi:10.1007/s00261-021-02979-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。